DJIA 17,335.76 140.34 0.82%
NASDAQ 4,624.05 57.91 1.27%
S&P 500 2,013.26 18.61 0.93%
market minute promo

ACTAVIS (NYSE: ACT)

243.99 0.78 (0.32%)

REAL-TIME: Last trade at


company name or ticker

Recent Quotes

ACT $243.99 0.32%
1D 1W 3M 6M 1Y 2Y 3Y
Today's Open $247.00
Previous Close $243.21
Daily Range $243.33 - $247.38
52-Week Range $153.42 - $249.94
Market Cap $64.5B
P/E Ratio 374.17
Dividend (Yield) $0.00 (0.0%)
Volume 333,356
Average Daily Volume 2,565,442
Current FY EPS $13.32

Sector

Healthcare

Industry

Drugs

ACTAVIS (ACT) Description

The Company is engaged in the development, manufacture, marketing, sale and distribution of brand and off-patent pharmaceutical products. Website: http://www.actavis.com/

News & Commentary

Actavis plc and Valeant Pharmaceuticals Inc. Battle for Allergan Inc.: Who Wins?

Valeant Pharmaceuticals upped its bid offer for Botox maker Allergan by $15 a share yesterday. Actavis reportedly responded with an even richer offer. Will activist investor Bill Ackman get his way or will six months of work go down the drain?

Mylan Beats, Raises Earnings Guidance; Abbott Deal on Track - Analyst Blog

Will Regeneron (REGN) Q3 Earnings be Hit by Higher Costs? - Analyst Blog

Pfizer's Trumenba Gains Accelerated Approval in the U.S. - Analyst Blog

Bernard Horn Comments on Actavis PLC

Abbott Labs Pays $250 Million for Topera in Heart Health Move

Biotech Rhythm Pharmaceuticals withdraws $86 million IPO citing acquisition agreement with Actavis

Analyst’s Top 4 Specialty Pharmaceutical Stocks to Buy Before Earnings

The Medicines Co.'s Angiomax Gets Favorable Court Ruling - Analyst Blog

3 Generics Stocks to Buy Now - Analyst Blog

Will Aegerion (AEGR) Disappoint This Earnings Season? - Analyst Blog

Will Aegerion (AEGR) Disappoint This Earnings Season? - Analyst Blog

See More ACT News...

ACT's Top Competitors

ACT $243.99 (0.32%)
Current stock: ACT
JNJ $107.46 (0.39%)
Current stock: JNJ
NVS $92.37 (0.46%)
Current stock: NVS
RHHBY $36.94 (-0.66%)
Current stock: RHHBY